Opko Health, Inc. (NASDAQ: OPK) reported a director-level purchase of company stock on March 20, 2026, according to a filing with the Securities and Exchange Commission. Director John A. Paganelli acquired 10,000 shares of common stock at $1.135 per share, a transaction that amounted to $11,350.
The purchase comes as the shares trade close to their 52-week low of $1.11, with a year-over-year decline of 36% in the stock price. The filing shows that, as a result of the transaction, Paganelli now directly holds 394,340 shares of Opko Health common stock. In addition, the filing states he has indirect ownership of 9,175 shares through his spouse.
Investment research noted in the filing context highlights that, according to InvestingPro analysis, the stock appears undervalued at current levels and that management has been actively repurchasing shares - an observation listed as one of more than 10 ProTips available to subscribers.
Separately, the company disclosed its fourth-quarter results for fiscal 2025. Opko Health reported an earnings per share (EPS) of -$0.04, which exceeded the analyst consensus expectation of -$0.07. Revenue for the quarter was $148.5 million, topping the forecasted $139.76 million. These figures indicate the company outperformed the specific analyst projections included with the filing.
In governance news, Opko Health has named Subbarao V. Uppaluri, Ph.D., to its board of directors. Dr. Uppaluri will fill the vacancy created by the death of Dr. Richard Krasno. The announcement states Dr. Uppaluri will serve as a director until the 2026 annual meeting of stockholders and is expected to join the board's Compensation Committee.
Taken together, the insider purchase, quarterly financial results, and board appointment represent recent developments at Opko Health. The purchase by a director is modest in dollar terms, while the reported quarter showed performance that exceeded the cited analyst expectations. The board change addresses a vacancy and assigns committee placement for the incoming director through the 2026 annual meeting.